Literature DB >> 31537898

Ethical, legal, and social issues (ELSI) in rare diseases: a landscape analysis from funders.

Adam L Hartman1, Anneliene Hechtelt Jonker2, Melissa A Parisi3, Daria Julkowska4, Nicole Lockhart5, Rosario Isasi6.   

Abstract

Recent interest in personalized medicine has highlighted the importance of research in ethical, legal, and social issues (ELSI). Issues in ELSI research may be magnified in the rare diseases population (i.e., small numbers of affected individuals, challenges in maintaining confidentiality, and paucity of treatments for diseases where natural history information may be limited). More than other areas of research, potential barriers include the lack of funding opportunities and appropriate review processes for applications to funding agencies. The ELSI Working Group of the International Rare Diseases Research Consortium (IRDiRC) performed an informal survey on ELSI funding initiatives to learn more about different funding mechanisms and to identify potential gaps in funding opportunities. The Working Group discusses these challenges and highlights the role of funding agencies and partners such as patient advocacy groups, specialists in social sciences and humanities, and clinicians to advance ELSI research in rare diseases.

Entities:  

Mesh:

Year:  2019        PMID: 31537898      PMCID: PMC6974597          DOI: 10.1038/s41431-019-0513-3

Source DB:  PubMed          Journal:  Eur J Hum Genet        ISSN: 1018-4813            Impact factor:   4.246


  23 in total

Review 1.  Why rare diseases are an important medical and social issue.

Authors:  Arrigo Schieppati; Jan-Inge Henter; Erica Daina; Anita Aperia
Journal:  Lancet       Date:  2008-06-14       Impact factor: 79.321

2.  Newborn Sequencing in Genomic Medicine and Public Health.

Authors:  Jonathan S Berg; Pankaj B Agrawal; Donald B Bailey; Alan H Beggs; Steven E Brenner; Amy M Brower; Julie A Cakici; Ozge Ceyhan-Birsoy; Kee Chan; Flavia Chen; Robert J Currier; Dmitry Dukhovny; Robert C Green; Julie Harris-Wai; Ingrid A Holm; Brenda Iglesias; Galen Joseph; Stephen F Kingsmore; Barbara A Koenig; Pui-Yan Kwok; John Lantos; Steven J Leeder; Megan A Lewis; Amy L McGuire; Laura V Milko; Sean D Mooney; Richard B Parad; Stacey Pereira; Joshua Petrikin; Bradford C Powell; Cynthia M Powell; Jennifer M Puck; Heidi L Rehm; Neil Risch; Myra Roche; Joseph T Shieh; Narayanan Veeraraghavan; Michael S Watson; Laurel Willig; Timothy W Yu; Tiina Urv; Anastasia L Wise
Journal:  Pediatrics       Date:  2017-01-17       Impact factor: 7.124

3.  Assessing the privacy risks of data sharing in genomics.

Authors:  C Heeney; N Hawkins; J de Vries; P Boddington; J Kaye
Journal:  Public Health Genomics       Date:  2010-03-29       Impact factor: 2.000

4.  Improving the informed consent process in international collaborative rare disease research: effective consent for effective research.

Authors:  Sabina Gainotti; Cathy Turner; Simon Woods; Anna Kole; Pauline McCormack; Hanns Lochmüller; Olaf Riess; Volker Straub; Manuel Posada; Domenica Taruscio; Deborah Mascalzoni
Journal:  Eur J Hum Genet       Date:  2016-02-10       Impact factor: 4.246

Review 5.  Progress in Rare Diseases Research 2010-2016: An IRDiRC Perspective.

Authors:  Hugh J S Dawkins; Ruxandra Draghia-Akli; Paul Lasko; Lilian P L Lau; Anneliene H Jonker; Christine M Cutillo; Ana Rath; Kym M Boycott; Gareth Baynam; Hanns Lochmüller; Petra Kaufmann; Yann Le Cam; Virginie Hivert; Christopher P Austin
Journal:  Clin Transl Sci       Date:  2017-10-23       Impact factor: 4.689

6.  Engaging the Canadian public on reimbursement decision-making for drugs for rare diseases: a national online survey.

Authors:  Julie Polisena; Michael Burgess; Craig Mitton; Larry D Lynd
Journal:  BMC Health Serv Res       Date:  2017-05-26       Impact factor: 2.655

7.  'You should at least ask'. The expectations, hopes and fears of rare disease patients on large-scale data and biomaterial sharing for genomics research.

Authors:  Pauline McCormack; Anna Kole; Sabina Gainotti; Deborah Mascalzoni; Caron Molster; Hanns Lochmüller; Simon Woods
Journal:  Eur J Hum Genet       Date:  2016-04-06       Impact factor: 4.246

8.  Framework for responsible sharing of genomic and health-related data.

Authors:  Bartha Maria Knoppers
Journal:  Hugo J       Date:  2014-10-17

Review 9.  Rare diseases under different levels of economic analysis: current activities, challenges and perspectives.

Authors:  Sara Cannizzo; Valentina Lorenzoni; Ilaria Palla; Salvatore Pirri; Leopoldo Trieste; Isotta Triulzi; Giuseppe Turchetti
Journal:  RMD Open       Date:  2018-11-12

10.  Big data phenotyping in rare diseases: some ethical issues.

Authors:  Nina Hallowell; Michael Parker; Christoffer Nellåker
Journal:  Genet Med       Date:  2019-02       Impact factor: 8.822

View more
  5 in total

Review 1.  Driving innovation for rare skin cancers: utilizing common tumours and machine learning to predict immune checkpoint inhibitor response.

Authors:  J S Hooiveld-Noeken; R S N Fehrmann; E G E de Vries; M Jalving
Journal:  Immunooncol Technol       Date:  2019-11-27

2.  So, and if it is not congenital adrenal hyperplasia? Addressing an undiagnosed case of genital ambiguity.

Authors:  Reinaldo Luna de Omena Filho; Reginaldo José Petroli; Fernanda Caroline Soardi; Débora de Paula Michelatto; Taís Nitsch Mazzola; Helena Fabbri-Scallet; Maricilda Palandi de Mello; Susane Vasconcelos Zanotti; Ida Cristina Gubert; Isabella Monlleo
Journal:  Ital J Pediatr       Date:  2022-06-10       Impact factor: 3.288

Review 3.  European expert network on rare communicable diseases and other rare diseases linked to mobility and globalisation focused on health care provision (EURaDMoG): a feasibility study.

Authors:  Ana Requena-Méndez; Zeno Bisoffi; Joan-Lluis Vives-Corrons; Joaquim Gascon; Antoni Plasència
Journal:  Orphanet J Rare Dis       Date:  2020-10-16       Impact factor: 4.123

4.  Three decades of ethical, legal, and social implications research: Looking back to chart a path forward.

Authors:  Deanne Dunbar Dolan; Sandra Soo-Jin Lee; Mildred K Cho
Journal:  Cell Genom       Date:  2022-06-27

Review 5.  Ethical, legal and social/societal implications (ELSI) of recall-by-genotype (RbG) and genotype-driven-research (GDR) approaches: a scoping review.

Authors:  Katharina Tschigg; Luca Consoli; Roberta Biasiotto; Deborah Mascalzoni
Journal:  Eur J Hum Genet       Date:  2022-06-15       Impact factor: 5.351

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.